Ben Stone
Corporate Officer/Principal chez ANAPTYSBIO, INC.
Postes actifs de Ben Stone
Sociétés | Poste | Début | Fin |
---|---|---|---|
ANAPTYSBIO, INC. | Corporate Officer/Principal | 01/01/2022 | - |
Historique de carrière de Ben Stone
Anciens postes connus de Ben Stone
Sociétés | Poste | Début | Fin |
---|---|---|---|
IconOVir Bio, Inc.
IconOVir Bio, Inc. BiotechnologyHealth Technology IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish. | Fondateur | - | - |
76bio, Inc.
76bio, Inc. Pharmaceuticals: MajorHealth Technology 76Bio, Inc. is a private company that aims to develop transformational therapies for patients with life-threatening diseases. The company is based in New York, NY. The company focuses on pioneering the next generation of degradation by design. 76Bio was founded by Joshua A. Kazam, David M. Tanen, Marius Pop, Christopher Wilfong, Ben Stone, Angela Koehler, Arie S. Belldegrun, and K. Dane Wittrup. Christopher Wilfong has been the CEO since incorporation. | Fondateur | - | - |
Formation de Ben Stone
University of Pennsylvania | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 6 |
Opérationnelle
Founder | 2 |
Undergraduate Degree | 2 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
ANAPTYSBIO, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
IconOVir Bio, Inc.
IconOVir Bio, Inc. BiotechnologyHealth Technology IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish. | Health Technology |
76bio, Inc.
76bio, Inc. Pharmaceuticals: MajorHealth Technology 76Bio, Inc. is a private company that aims to develop transformational therapies for patients with life-threatening diseases. The company is based in New York, NY. The company focuses on pioneering the next generation of degradation by design. 76Bio was founded by Joshua A. Kazam, David M. Tanen, Marius Pop, Christopher Wilfong, Ben Stone, Angela Koehler, Arie S. Belldegrun, and K. Dane Wittrup. Christopher Wilfong has been the CEO since incorporation. | Health Technology |